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Reactive oxygen species 
A B S T R A C T   
Molecular mechanisms underlying development and progression of gastrointestinal (GI) cancers are mediated by 
both oxidative stress (OS) and microRNAs (miRNAs) involvement. Notably, OS signaling may regulate the 
expression of miRNAs, and miRNAs function as imperative players in OS-initiated tumors. Given the defined 
biological roles of both OS systems and miRNAs in GI carcinogenesis, a possible interplay between these two key 
cellular networks is considered. A growing body of evidence has indicated a reciprocal connection between OS 
signaling pathways and miRNA regulatory machines in GI cancer development and progression. Illumination of 
the molecular cross-talking between miRNAs and the OS would improve our pathophysiological insight into 
carcinogens. Also, understanding the molecular mechanisms in which these systems are reciprocally regulated 
may imply in future medical practice mainly GI cancer therapy. Nowadays, therapeutic strategies focusing on 
miRNA and OS in GI cancer treatment are increasingly delineated. Since the use of antioxidants is limited owing 
to the contrasting consequences of OS signaling in cancer, the discovery of OS-responsive miRNAs may provide a 
potential new strategy to overcome OS-mediated GI carcinogenesis. Given the possible interaction between OS 
and miRNAs in GI cancers, this review aimed to elucidate the existing evidence on the interaction between OS 
and miRNA regulatory machinery and its role in GI carcinogenesis. In this regard, we will illustrate the function 
of miRNAs which target OS systems during homeostasis and tumorigenesis. We also discuss the biological cross- 
talk between OS systems and miRNAs and corresponding cell signaling pathways.   
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1. Introduction 
The gastrointestinal (GI) system-related cancers are responsible for 
more cancers morbidity and mortality than any other systems in the 
body [1]. Approximately 30 % of cancer incidence and 32 % of cancer 
deaths are due to GI malignancies (colorectum, stomach, liver, 
oesophagus and pancreas) worldwide [2]. The etiology and risk factors 
of GI cancers to some extent are associated with genetic background, 
inflammation and co-infections, obesity, liver cirrhosis, metabolic dis-
orders, tobacco use, dietary factors and chronic oxidative stress [3,4]. 
Oxidative stress (OS), refers to the redox imbalance with overproduction 
of reactive oxygen species (ROS) above the ability of antioxidant defense 
[5,6]. In this regard, increasing investigations have revealed that the GI 
is the main place of oxidant and antioxidant occurrences [7,8]. 
OS-activated signaling pathways have been frequently associated with 
the development and progression of numerous solid malignancies, 
including GI cancers [9]. From the biological point of view, 
cancer-related OS signaling pathways are implicated as a network, as 
well as, interplay between OS and related genes. Non-coding RNAs, 
including microRNAs (miRNAs) comprise the functional players in gene 
regulation and have recently been demonstrated to be involved in 
cancer-associated OS signaling pathways. In this view, OS signaling has 
been revealed to regulate the expression of miRNAs that may function as 
imperative players in OS-derived tumors. A line of evidence suggests a 
reciprocal connection between OS signaling pathways and miRNA reg-
ulatory machines in GI cancer development and progression. In this 
review, we elucidate the interaction between OS and miRNAs and focus 
on biological aspects of this network signaling in GI carcinogenesis. We 
highlight the possible function of miRNAs which target OS systems 
during homeostasis and tumorigenesis and discuss the corresponding 
biological cross-talking and cell signaling pathways. 
2. OS signaling pathway in Cancer development 
Cellular metabolism usually produces ROS, indicating as the key 
inducers of various signaling pathways in intra- and extracellular envi-
ronmental circumstances [10]. Low levels of ROS can act as a cellular 
signal that changes protein structure and activity through oxidizing the 
thiol groups of amino acids. Whilst, higher amounts of ROS may disturb 
cellular function by attacking lipids, proteins, and DNA [11]. OS and 
redox signaling have been to be involved in the cancer development, so 
that ROS can affect the characteristics of cancer cells and their reactivity 
to growth signals as well as cellular homeostasis [12]. Moreover, 
oxidative damage to DNA has been documented to definitely sensitize 
cells to cancer-associated mutations. Taken together, OS activation can 
promote cancer-initiated episodes and indirectly lead to cancer devel-
opment [12]. 
3. MiRNAs regulatory systems and Cancer 
MiRNAs are characterized as small non-coding RNAs of 18–23 nu-
cleotides, which negatively regulate gene expression through targeting 
the mRNA [13]. MiRNA molecules are commonly transcribed by RNA 
polymerase II/III as immature primary miRNAs (pri-miRNAs). After a 
two-step processing of pri-miRNA in the nucleus by Dicer (endor-
ibonuclease Dicer or helicase with RNase motif) and Drosha (a class 2 
ribonuclease III enzyme) complexes, the mature form of miRNA is 
created [14]. In the cytoplasm, the mature miRNA is combined with the 
RNA-induced silencing complex (RISC) to act as a functional miRNA. 
Cytoplasmic mature functional miRNAs typically regulate the gene 
expression by post-transcriptionally suppressing the translation or 
inducing mRNA degradation by binding to 3′ untranslated region (UTR) 
sequence [15,16]. Notably, the miRNA database (miRBase) [17], 
released in June 2014, indicated the existence of approximately 2588 
mature miRNAs in human. It has been estimated that miRNAs regulate 
~60 % of human genes [18]. Many studies have shown that miRNAs are 
associated with the pathophysiology and treatment of cancers [19]. 
Growing evidence indicates that miRNA can involve in tumorigenesis by 
regulating various oncogenes and tumor suppressor genes. Cellular 
functions of miRNAs impact on various aspects of tumor development 
including cell proliferation [20], tumor growth, spread, metastatic 
ability [21], apoptosis [22]and angiogenesis [23]. A range of genes 
regulated by miRNAs has been specified to be related to tumor growth 
and aggressiveness [24]. In this regard, miRNA profiles of tumors can 
clarify patient survival and intervention respond [25,26]. A line of ev-
idence also represents the possible ability of cell-free circulating miRNAs 
in the clinic as biomarkers for cancer diagnosis and prognosis [27]. 
Cancer-related miRNA biomarkers can even be found in biological fluids 
like plasma, saliva and urine, as well as amniotic and seminal fluids 
providing the possibility of a less-invasive monitoring [28]. MiRNA 
dys-regulation in cancer pathophysiology was first got attention when a 
cluster of miRNAs, was detected at frequently deleted sequences in 
malignancies [29]. Recently, more interests have concentrated on 
evaluating the changes in miRNA expression pattern to detect novel 
cancer biomarkers and therapeutic strategies [30]. 
4. Interaction of miRNAs and OS in Cancer 
Since both miRNAs and OS are affected/ dysregulated in patholog-
ical circumstances, including cancer, it is critical to find out the bio-
logical interplay between miRNAs and OS. Notably, ROS, including 
hydrogen peroxide (H2O2), hydroxide (OH− ) and superoxide (O2− ) cause 
damage to cell lipids, proteins, RNA, and DNA [31]. To maintain redox 
homeostasis, the body has an antioxidant defense system composed of 
various enzymes such as superoxide dismutase (SOD), glutathione 
peroxidase (GPXs), and catalase (CAT) to scavenge ROS. One of the 
important functions of ROS is stimulating the NF-E2-related factor 
(Nrf2)-mediated activation of an antioxidant response element (ARE) to 
defend cells and body against OS [32]. Nrf2 was confirmed to tran-
scriptionally regulate the expression of multiple critical enzymes of 
anti-oxidative defense [33,34]. The activation of Nrf2-ARE pathway, in 
turn, leads to induction of anti-oxidative defense enzymes, i.e. heme 
oxygenase-1 (HO1), NAD(P)H quinoneoxidoreductase 1 (NQO1), 
glutathione S-transferase (GSTs), SOD and glutathione peroxidase 
(GPXs) [35,36]. Nrf2 is controlled by its repressing protein Kelch-like 
ECH-associated protein 1 (KEAP1) [37]. Recent studies have shown 
that multiple miRNAs are capable of regulating Nrf2 and KEAP1. For 
example, it has been demonstrated that miR-7 inhibits KEAP1 in brain 
cells [38]. Also miR-141 could activate Nrf2 signaling via selectively 
suppressing KEAP1, that decreases UV-induced OS and apoptosis [39]. 
5. MiRNA biogenesis is regulated by OS signaling pathways 
Given the potential role of oxidative stress components in the regu-
lation of gene expression, OS-mediated control of miRNA biogenesis has 
been investigated in several studies (Table 1). OS activation, that plays a 
critical role in the initiation and development of cancer, seems to 
regulate the number of miRNAs in tumorigenesis. Notably, promoted OS 
is one of the primary biological signal and biochemical features that 
functions to promote cancer-associated miRNAs (oncomiRs) [40]. It has 
been shown that the expression of Dicer was down-regulated by OS in 
cerebromicrovascular endothelial cells (CMVECs) [41]. A line of evi-
dence has suggested the biological role of Dicer in a feedback loop that 
affects ROS activation resulting in cellular homeostasis. In this view, 
H2O2 treatment leads to down-regulation of the Dicer and decreased 
miRNA expression [41,42]. 
Accumulating studies have revealed that oxidative stress system 
mainly modulates the expression of miRNAs via targeting various 
transcription and epigenetic factors [43,44]. Indeed, miRNAs affected 
by OS (named redoximiRs), act as regulators of target gene expression in 
response to oxidative stress system. For example, it has been reported 
that H2O2 treatment can cause cell degeneration by enhancing OS. These 
A. Akbari et al.                                                                                                                                                                                                                                  
Biomedicine & Pharmacotherapy 131 (2020) 110729
3
interventions increased the expression of miR-153, targeting and 
reducing the level of Nrf2. A decrease in Nrf2, in turn, would elevate OS 
due to a reduction in the amounts of antioxidant enzymes [45]. On the 
other hand, various factors that generate ROS (ionizing radiation, H2O2, 
UV) are recognized to induce modulation of miRNA expression [44,46]. 
Multiple studies have highlighted the miRNA regulatory systems by OS 
signaling pathways in various cancers, indicating the critical role of 
OS-mediated control of miRNAs in tumorigenesis. Likewise, several 
miRNAs were identified to be modulated by cytotoxicity and OS, 
including miR-200 and miR-34a, which are induced by OS [43,44]. A 
miRNA profiling of human umbilical endothelial cells (HUVEC) exposed 
to 200 μM H2O2, revealed an up-regulation of miR-200 family 
(miR-200a, miR-200b, miR-429, miR-200c and miR-141) [44]. These 
miRNAs have been broadly investigated for their capacity to promote 
epithelial to mesenchymal transition in the tumor cells [47]. Functional 
investigations of possible cross-talk between OS and the aforementioned 
miRNAs have shown that cellular OS sensitizes tumors to chemotherapy 
through regulating miR-141 and miR-200a synthesis [48]. A distinctive 
pathway indicated the effects of OS on miRNA regulation are silent 
mating-type information regulation 2 homolog (SIRT1)-mediated 
metabolic signaling pathway. Sirtuin 1 or SIRT1 is characterized as an 
NAD+-dependent class III histone deacetylase [49]. This protein is 
up-regulated under specific circumstances including; caloric restriction 
(CR) and OS [50]. As SIRT1 gene expression can be controlled at both 
transcriptional and post-translational levels, it is possible that underly-
ing molecular mechanisms and effectors such as OS modulate SIRT1 
through miRNAs [51]. MiR-34a was the first reported miRNA 
down-regulated by SIRT1 in the cellular aging-associated OS [52]. 
Numerous other miRNAs, including miR-141, miR-181, and miR-199, 
were also shown to down-regulate SIRT1 in different cells/tissues. For 
example, decreased expression of miR-199 in hypoxic circumstances, 
can lead to up-regulation of SIRT1 and reduction of apoptosis [53]. 
There are findings demonstrating that OS activates stress-related tran-
scription factors such as nuclear factor-κB (NF-κB), p53, forkhead box O 
(FOXO), hypoxia-inducible factor (HIF), and c-jun through miRNAs 
regulation [54,55]. 
Tumor suppressor protein p53 is a major molecule in maintaining 
genomic stability by regulating several downstream genes involved in 
cell cycle arrest, apoptosis and senescence [56,57]. As a cellular tran-
scription factor associated with OS, ROS can induce p53 expression by 
activating downstream genes for preserving the genome integrity [58]. 
Moreover, p53 is connected with miRNA processing machinery by 
inducing post-transcriptional maturation of different suppressor miR-
NAs, including miR-143, miR-16-1, and miR-145 [59]. In addition, p53 
has been documented to induce a number of stress-related miRNAs such 
as miR-34 and miR-200 [60]. MiR-200 functions as a tumor inhibitor by 
suppressing the EMT process, an initial/critical step for cancer invasion 
and development [61]. Increased expression of miR-200 has been 
revealed to cause a reversal of EMT in several cancers such as gastric, 
pancreatic, bladder, and prostate [62]. MiR-200 may also act as a link 
between oxidative stress and various transcriptional factors, including 
FOXO family [49]. FOXO family transcriptional factors include four key 
proteins: FOXO1, FOXO3, FOXO4 and FOXO6. At the cytoplasmic level, 
downstream target genes of FOXO are implicated in the regulation of 
cell cycle, OS resistance, apoptosis, and cellular metabolism [63]. NF-κB 
is another transcriptional factor that is influenced by OS through miRNA 
regulatory system [64]. The elevated ROS activates NF-κB, indicating it 
as a redox-sensitive TF that promotes apoptosis [65]. Recent studies 
have also shown that up-regulation of miR-27b, attenuates OS circum-
stances, resulting in inhibition of lipopolysaccharide-induced activation 
of NF-kB [66]. Table 1 indicated a number of OS mediators that could 
regulate miRNA expression profile to control ROS activation. 
6. OS signaling pathway is modulated by the miRNA regulatory 
system 
In addition to the regulatory effects of OS on miRNAs activity and 
transcriptional status, miRNAs are reciprocally able to modulate redox 
homeostasis by an OS defense system. The miRNA-mediated control of 
the OS either as an inhibitor or promoter has also been observed. Some 
miRNAs may alter ROS amounts and contribute to regulate downstream 
biological functions by means of targeting specific genes associated with 
ROS generation (Table 2) [43]. A cross-talk between miRNAs and 
modulators of the ROS system has been proposed in which the tran-
scription, biogenesis and maturation of miRNAs are controlled by the 
redox system. One of the main pathways by which miRNAs affect OS 
system is targeting the transcriptional factors. Various transcription 
factors (TFs) and kinases as key redox modulators are well-established to 
initiate and contribute to cellular redox signaling [66]. 
We have investigated some miRNAs that affect OS through TFs. For 
example, miR-33a down-regulates the expression of SIRT1 and SIRT6, 
modulating the biogenesis of lactate dehydrogenase (LDH) and ROS 
signaling [67]. MiR-29b also has been shown to exert a protective effect 
against H2O2 toxicity and OS through SIRT1 modulation [68]. Addi-
tionally, miR-128 sensitized colon cancer cells to tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity 
by inducing apoptosis [69]. 
Inhibition of miR-155 by targeting transcription factor Nrf2 has been 
confirmed to increase apoptosis and cell death [70]. MiR-125b was also 
shown to regulate peroxiredoxin-like 2A (PRXL2A), an antioxidant 
factor that protects cells from OS. Down-regulation of miR-125b inhibits 
the up-regulation of PRXL2A, in turn, defends the tumor cells from OS. 
Also, miR-125b-PRXL2A axis and downstream cascade were discovered 
to be an upstream effector of the Nrf2 [71]. Given the critical role of Nrf2 
in the OS-related homeostasis, miR-144 has been exhibited to directly 
affect the cellular resistance to OS through modulation of Nrf2 expres-
sion. In this way, miR-144 overexpression causes a remarkable decrease 
of Nrf2 protein expression. Moreover, miR-144 can decrease antioxidant 
response elements (AREs)-driven gene expression and reduces cellular 
levels of GSH [72]. 
Some miRNAs may directly regulate OS-related enzymes or other 
molecular effectors. For example, it has been shown that several miRNAs 
can regulate the expression of GPXs [73]. Another study showed that 
miR-330-3p increased the metastasis of human cancer cells by inhibiting 
the manganese superoxide dismutase (hSOD2b) expression, a strong 
antioxidant enzyme [74]. However, other miRNAs such as miR-509-5p 
have been demonstrated to have tumor-suppressive effects on breast 
Table 1 
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cancer cell invasion and metastasis via targeting SOD2 [75]. Increased 
miR-135a can suppress cell OS through modulating toll-like receptor 4 
(TLR4) [76]. MiR-661 was demonstrated to have a potential relevant 
epigenetic regulatory role in OS and cell metabolism in colon cancer 
cells [77], while miR-143 increased OS in HCT116 human colon cancer 
cells [78]. 
Some miRNAs may directly affect OS-mediated enzymes or factors. 
For example, miR-921 suppresses the expression of glutathione peroxi-
dase 3 (GPX3), a main antioxidant enzyme in plasma [79]. Another 
study showed that miR-330-3p increased metastasis of cancer cells by 
inhibiting of human manganese superoxide dismutase (hSOD2b) 
expression, a strong antioxidant enzyme [74]. However, another miR-
NAs such as miR-509-5p has been found to have tumor-suppressive ef-
fects on breast cancer cell invasion and metastasis via targeting SOD2 
[75]. Table 2 designated several miRNAs that potentially target 
OS-associated effectors to regulate ROS activation in carcinogenesis. 
7. Underlying molecular mechanisms of gastrointestinal 
carcinogenesis 
The malignancies in the GI system are pathologically heterogeneous 
and molecular and cellular aberrations have frequently been described. 
GI carcinogenesis is well-known to be mediated by multifaceted genetic 
and epigenetic events. Genetics (various proto-oncogenes and tumor 
suppressor genes) and epigenetics (DNA methylation, histone modifi-
cation, chromatin remodeling, and non-coding RNAs) coregulate the GI 
cancer initiation and progression [80]. Aberrant epigenetic modifica-
tions play a fundamental role in the formation of GI cancers [80]. 
Cell signaling pathways involved in GI tumorigenesis such as RAS/ 
BRAF, PI3K/Akt, WNT/ß-catenin, JAK/STAT3, PPAR and a range of 
corresponding TFs have been well-studied [81]. Recently, the biological 
roles of non-coding RNAs particularly long non-coding RNAs (lncRNAs) 
and miRNAs have been increasingly identified in GI cancers. It has 
frequently been demonstrated that miRNAs modulate the expression of 
genes involved in gastrointestinal pathological conditions by affecting 
the cell growth, phenotype switch, fibrogenesis, ROS production, and 
response to stress and aging [18,82]. Recent investigations have estab-
lished that numerous miRNAs may be dysregulated in GI malignancies, 
indicating them as tumor modulators [83]. Several studies have inves-
tigated the expression of the miRNAs in colorectal malignancies and 
found that miR-143 and miR-145 function as potential regulators in 
tumorigenesis [84]. In this regard, it has also been confirmed that some 
of miRNAs exert their biological roles in cancers through modulating OS 
factors. For example, miR-210 (with a HIF-1α-binding site in its pro-
moter) was revealed to be remarkably up-regulated in hypoxia condi-
tions and increase tumorigenesis in colon, pancreatic, and breast cancers 
[85]. It has been substantiated that hypoxia leads to angiogenesis in the 
initiation and development of cancers. In contrast, a number of miRNAs 
have protective effects on carcinogenesis. For example, recent studies 
have demonstrated that miR-143 overexpression could promote cell 
apoptosis, and decrease colon tumor development, in vivo [86]. In the 
same way, miR-145 up-regulation has been reported to modulate 
apoptosis, and suppress colon cancer cell growth and proliferation [87, 
88]. 
8. Cross-talk between oxidative stress signaling and miRNAs 
regulatory systems in GI cancers 
Given the pivotal roles of a variety of TFs, ROS and noncoding RNAs 
in GI cancers, explaining the relationship between these factors can in-
crease insight into molecular identification as well as targeted therapies 
[81]. As mentioned above, OS and miRNA axis and corresponding 
signaling pathways may be considered as fundamental pathways in GI 
cancer development (Fig. 1). Increasing evidence suggests that contin-
uous OS can induce oncomiRNA-associated cascades leading to gastro-
intestinal diseases and carcinogenesis. Reciprocally, miRNA network 
regulates OS signaling effectors and consequent molecular events 
involved in GI cancers (Fig. 1). In the following, we review the inter-
action between OS and miRNA regulatory systems in gastrointestinal 
cancers. In this regard, we point out the function of miRNAs which 
target OS systems and discuss the cross-talk between OS and miRNAs 
during GI tumorigenesis. 
8.1. Colorectal Cancer 
Given that the underlying mechanisms associated with both miRNAs 
Table 2 
Several miRNAs that potentially target OS-associated effectors to regulate ROS activation in carcinogenesis.  
MiRNA Oxidant/antioxidant- mediated 
signaling 
Target gene/proteins Biological function Ref 
miR-15 and miR-16 Oxidant BCL2 Inhibition of apoptosis (Hanahan, 2011) 
miR-7 Antioxidant KEAP1 Promotion of antioxidant enzymes (Kabaria, 2015) 
miR-141 Antioxidant KEAP1 Promotion of antioxidant enzymes (Cheng, 2017) 
miR-34a Oxidant SIRT1 Increase of apoptosis (Cheng, 2017) 
miR-27b Oxidant NF-κB Increase of apoptosis (Thulasingam, 
2011) 
miR-33a Antioxidant SIRT6 Elevation of LDH and ROS (Chang, 2017) 
Mir-29b Antioxidant SIRT1 Inhibition of H2O2-induced damage (Hou, 2017) 
miR-128 Oxidant SIRT1 Increase of apoptosis (Lian, 2018) 
miR-155 Oxidant Nrf2 Inhibition of apoptosis (Chen, 2017) 
miR-125b Antioxidant PRXL2A Inhibition of apoptosis (Chen, 2019) 
miR-135a Antioxidant TLR4 Reduction of ROS, MDA, and induction of SOD (Du, 2018) 
miR-74661 Oxidant hexose-6-p-deh and pyruvate 
kinase M2 
Promotion of an epithelial-to-mesenchymal 
transition phenotype 
(Gomez, 2017) 
miR-921 Oxidant GPX3 Suppression of GPXx3 (Choi, 2019) 
miR-330-3p Oxidant hSOD2b Suppression of SOD (Shen, 2019) 
miR-509-5p Antioxidant SOD2 Increase of SOD (Song, 2017) 
miR-21 Oxidant hOGG1 Reduction of T-AOC, SOD, CAT, promotion of 8- 
OHdG 
(Tu, 2014) 
miR-30 Antioxidant P53 Induction of apoptosis (Wang, 2017) 
miR-6785-5p and miR- 
642a-3p 
Antioxidant FOXO4 Increase of chemosensitivity (Yu, 2015) 
miR-10a Antioxidant Homeobox genes Regulation of cell invasion /migration (Matsushima, 
2010) 
miR-10b Antioxidant KLF4 Regulation of esophageal cancer cell invasion and 
migration 
(Tian, 2010)  
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and OS system were described in colorectal cancer (CRC), it is funda-
mental to identify their possible role of cross-talking regarding tumori-
genesis [89,90]. Expression analysis of miRNAs and functional 
examinations in colon cancer cells have shown that key cellular path-
ways, such as cell apoptosis, response to OS and protein folding are 
regulated by miRNA system [89]. GRP94, SOD1 and annexin II (ANXA2) 
proteins are characterized as corresponding targets down-regulated by 
miR-143 or miR-145 [78]. These proteins are involved in OS signaling 
pathways and apoptosis regulation in tumor cells. In addition, 
miRNA-661 has been proposed to play a critical role as an epigenetic 
modulator of colon cancer cell metabolism. MiR-661 promotes ROS, 
particularly mitochondria-derived SO contributes in 
epithelial-mesenchymal transition (EMT) phenotype in non-metastatic 
colon cancer cells. This signaling axis also may cause an increased 
tumor cell sensitivity to OS [77]. MiR-34 expression in CRC cells is 
remarkably associated with the amount of inducible nitric oxide syn-
thase (iNOS). Elevated NO may be as a an important factor in the se-
lection of cells with a low level of p53-dependent miRNAs that are 
responsible for tumor development and progression [91]. 
in vitro studies showed that antioxidant and anti-inflammatory drugs 
such as curcumin [92] and Ethyl 2-((2,3-bis(nitrooxy)propyl) 
disulfanyl)benzoate (GT-094) [93] inhibit cell proliferation and induce 
apoptosis through downregulating miRNA-27a and inducing zinc finger 
and BTB domain containing 10 (ZBTB10). Both in vitro and in vivo 
studies have demonstrated that miR-124 functions as a tumor inhibitor 
and a regulator of energy homeostasis through a polypyrimidine 
tract-binding protein 1 (PTB1), pyruvate kinase muscles 1 and 2 
(PKM1and PKM2) feedback cascade in human colorectal tumor cells 
[94]. MiR-210 up-regulation was found to promote ROS synthesis in 
colorectal tumor cells. MiR-210 can down-regulate mitochondrial 
iron-sulfur cluster scaffold homologue and contribute to mitochondrial 
activity in OS activation [95]. MiR-210 was also established to induce 
OS activation under hypoxic condition, resulting in an invasive and 
progressive CRC [89]. In addition, miR-210-induced apoptosis by 
increased ROS has been described in CRC [89]. Furthermore, 
up-regulation of miR-141 and miR-200a was revealed to regulate ROS 
production and tumor proliferation by targeting p38a (Fig. 1) [96]. 
8.2. Gastric Cancer 
ROS production has been reported to cause a dysregulated expres-
sion of miRNAs in gastric cancer (GC). According to recent reports, 
Fig. 1. Schematic graph illustrating molecular cross-talking between ROS production and the miRNA regulation in the underlying mechanisms of GI 
cancers. Molecular mechanisms of ROS activation may be involved in the regulation of the miRNA expression in GI cancers by affecting the miRNA biogenesis and 
transcription. ROS activation also can increase or inhibit transcriptional factors (P53, NFκB, HIF1α, c-Myc and NRF2) and epigenetic factors to regulate miRNAs in GI 
carcinogenesis. Reciprocally, miRNAs can modulate OS system through targeting the upstream genes and corresponding signaling pathways. Therefore, a potential 
cross-talking between ROS, TFs and miRNAs contribute to regulate cell growth, cell cycle, apoptosis, tumor development and progression. 
* ROS; reactive oxygen species, GI; gastrointestinal, TF; transcription factor. 
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epigenetic elements play a major role in gastric carcinogenesis during 
OS activation (Fig. 1). ROS may promote the methylation of several 
miRNA genes, such asmiR-329, miR-199, miR-145-5p, miR-125, and 
miR-362-3p, resulting in promoting GC progression, [97–99]. In addi-
tion miRNAs and Circular RNAs (circRNAs) expression profles has been 
revealed to be a potential biomarkers involved in GC [100]. Moreover, 
in helicobacter pylori-induced GC, reduced expression of miR-328 has 
been reported to be involved in ROS generation [101]. In GC, hypoxia 
can also change the expression of miRNAs. For instance, miR-495 was 
demonstrated to be up-regulated in two gastric cell lines, SNU484 and 
SNU5, under hypoxic circumstances [102]. Overexpression of miR-21 
can decrease total anti-oxidation competence (T-AOC), SOD and CAT, 
but increases 8-oxo-deoxyguanosine (8-OHdG) and human 8-oxogua-
nine DNA N-glycosylase 1 (hOGG) mRNA. Moreover, the expression 
levels of miR-21 have been found to be negatively associated with 
programmed cell death 4 protein (PDCD4) in gastric cancer cells [103]. 
Hsa-let-7 g also exerts an anti-tumor effect which is induced by ox-LDL. 
This miRNA promotes the sensitivity of gastric cancer cells to OS by 
indirect inhibition of DNA damage response genes [104]. 
Interestingly, gastric cancer cell apoptosis was observed to be 
mediated by a group of antioxidants and miR-143, indicating miR-143 
could increase the chemical sensitivity of the antioxidants through 
autophagy suppression [105]. Bacterial infection and ROS stimulation 
can down-regulate the expression of miR-17-92 cluster in gastric cancer 
cell lines [106]. The miR-17-92 cluster is an instance of miRNAs with 
both oncogenic and tumor suppressive effects, based on cancer type. 
This group of miRNAs was found to be down-regulated in DNA damage 
via a p53-dependent process or due to excessive ROS [107,108]. 
Furthermore, down-regulation of miR-30 in gastric cancer has reported 
to elevate ROS production which is suppressed by p53. Therefore, 
miR-30 was concluded to act as a potential suppressor miRNA through 
p53/ROS-mediated modulation of the mitochondrial apoptotic pathway 
in GC [109]. Moreover, downregulation of miR-6785-5p and 
miR-642a-3p and subsequent enhancing FOXO4 expression were shown 
to increase chemosensitivity of resistant gastric carcinoma cells [110]. 
In several GI cancers, especially GC and CRC, inflammation and OS are 
frequently well-depicted to contribute to the development and pro-
gression of cancer. Peroxisome proliferator-activated receptor gamma 
(PPARγ) has been reported to be down-regulated through inflammation 
and OS in GC and CRC [111]. Conversely, the WNT/β-catenin pathway is 
commonly activated in these cancers. A number of downstream 
signaling pathways and related target genes such as c-Myc, cyclin D1 
and HIF-1α are implicated in the development of GC and CRC. Tran-
scription factor NFκB, as and activator of various inflammatory and 
growth factors, can promote the ROS synthesis via inducing nitric oxide 
synthase enzyme. ROS activation can reciprocally motivate the expres-
sion and activation of inflammatory factor NFκB, activator protein-1, 
HIF-1α, stimulating the canonical WNT pathway [111]. Moreover, 
ROS was confirmed to trigger the phosphatidylinositol 3 kinase/protein 
kinase B (PI3K/Akt) signaling pathway in the malignancies. Aforemen-
tioned signaling network concerning the WNT/β-catenin pathway and 
PPARγ in ROS regulation was observed to be modulated by miRNA 
systems [111]. So, up-regulation of miR-451 can promote WNT/β-ca-
tenin signaling pathway and several downstream signaling, including 
c-Myc and PI3K/AKt in GC. The activation of these signaling pathways 
may activate HIF-1α that stimulates the ROS synthesis [111]. 
8.3. Hepatocellular Cancer 
The critical role of miRNAs in the multiple stages of chronic liver 
complications in the development of liver cancer has been identified 
[112,113]. Recent findings confirmed the effect of ROS-mediated 
oxidative DNA damage to hepatocellular carcinoma (HCC), and in this 
way, dys-regulation of some miRNAs was described. For example, 
over-expression of miR-92, with a role in both the apoptotic process and 
cellular proliferation pathways, was associated with increased risk of 
HCC [114]. In addition, recent researches demonstrated a remarkable 
positive association between miRNA-92 expressions and Hepadna 
virus-associated carcinogenesis in HCC tissues. Besides, studies showed 
that miRNA-122a, miRNA-195, miRNA-199b, and miRNA-199a are 
down-regulated in the most (55 %–70 %) of HCCs, while miRNA-222 is 
up-regulated in the malignancy [114,115]. MiRNAs also were recog-
nized as key players to be involved in the regulation of iron homeostasis 
in pathology of HCC [116]. Accordingly, investigation of OS parameters 
and miRNAs and the corresponding molecular mediators were proposed 
as a new strategy for HCC diagnosis and prognosis. In this regard, it was 
recognized four OS-responsive miRNAs, which were modulated by a 
p53-independent (miR-638 and miR-150-3p) manner and 
p53-dependent pathway (miR-1915-3p and miR-34a-5p) [117]. As 
mentioned earlier, miR-210 induces under hypoxic conditions and can 
function as an oncomiR in tumorigenesis. It was found that transcription 
factor HIF-1α can regulate the miR-210 expression by binding to the 
miR-210 promoter via hypoxia response element (HRE). On the other 
hand, some findings show ROS activation is connected to the telomerase 
activity in HCC. The interplay between ROS regulation and telomerase 
activity is related to HIF-1α signaling (Fig. 1). So that, HIF-1α was 
revealed to induce and promote corresponding downstream signaling 
pathway triggered by ROS [118]. 
ROS exposure has also been shown to be correlated with oncogenic 
signals such as those transduced by c-Myc and Ras. c-Myc, a well-known 
oncogene, is involved in tumor growth, migration, invasion and 
metastasis through the regulation of gene expression. c-Myc activation 
induces DNA damage in normal human fibroblasts. This effect has been 
correlated with ROS generation [119]. The expression levels of 
miR-17-92 were remarkably inhibited by triptolide in a c-Myc-depend-
ent manner, which resulted in the induction of target genes, including 
phosphatase and tensin homolog (PTEN), bcl-2 interacting mediator 
(BIM) and p21, in HCC cells [120]. 
8.4. Esophageal Cancer 
Accumulating investigations indicated dysregulation of miRNAs in 
esophagus pathological conditions. It was hypothesized that miRNAs 
expression could be used to distinguish patients who have a high risk for 
esophageal dysplasia, Barrett esophagus, esophageal cancer (EC), and 
esophageal squamous cell carcinoma (ESCC) [121]. It has also been 
identified that miR-205 and miR-10a are remarkably changed, and 
possibly have pivotal functions in the pathogenesis of ESCC. As an 
outcome of the mechanistically investigation on miR-205, it was vali-
dated that this miRNA could regulate the epithelial-mesenchymal 
transition program by decreasing the levels of E-cadherin. This biolog-
ical event is characterized as an important miRNA regulation of ESCC in 
which representative E-cadherin inhibitors, zinc finger E-box binding 
homeobox 1(ZEB1) and ZEB2 are suppressed. In the same way, miR-10a 
is recognized as a tumor inhibitor owing to regulate cell invasion/mi-
gration via affecting homeobox genes [122]. MicRNA-10b Also reduces 
cell invasion and migration by inhibiting Kruppel-like factor 4 (KLF4; a 
known tumor suppressor gene which inhibits cell invasion and migra-
tion) in esophageal cancer cell lines [123]. 
However, the biological role of oxidative stress and ROS activation in 
ESCC has not been well investigated. One study examined the under-
lying molecular mechanisms of oxidative stress induced by H2O2 in the 
ESCC cells. The results of this study showed that H2O2 could promote 
cell death in tumor cells via the activation of poly (ADP-ribose) poly-
merase 1 (PARP1), Caspase 3, and Caspase 9. Hence, the findings sug-
gested that H2O2 may be involved in mitochondrial dysfunction by 
promoting the ROS synthesis, regulating cell growth [124]. Another 
study showed that several suppressor miRNAs, including miR-507, miR 
-634, miR-450a, and miR-129-5p can target/inhibit the Nrf2 pathway. 
Given the pivotal function of the Nrf2 signaling pathway in ROS and 
antioxidant responses, a miRNA-mediated ROS regulation may be hy-
pothesized to involve in ESCC tumorigenesis. 
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8.5. Pancreatic Cancer 
MiRNAs have been associated with various cellular processes in 
pancreatic cancer (PC) development and progression. MiRNAs have 
confirmed to be modulated by a metabolic function of the pancreas, in 
parallel, miRNAs can regulate and change metabolic function (Fig. 1). 
The corresponding signaling networks are served as key important un-
derlying mechanisms in pancreatic neoplasms [125]. For instance, 
overexpression of miR-155 leads to suppression of Foxo3a, reducing 
most important antioxidants enzymes such as superoxide dismutase 
(SOD2) and catalase (CAT), increasing the ROS generation and 
pancreatic cell proliferation [126]. Additionally, phosphorylation of the 
signal transducer and activator of transcription 3 (STAT3) was also 
down-regulated by miR-216a, whereas the anti-miR-216a treatment had 
an opposite effect. Treatment of pancreatic cancer cells with miR-216a 
significantly inhibited cell growth and promoted cell apoptosis. In 
addition, the downstream genes of JAK2/STAT3, survivin and X-linked 
inhibitor of apoptosis protein, as anti‑apoptotic genes, were also 
decreased by miR-216a. Moreover, miR-216a overexpression can 
noticeably inhibit the JAK2/STAT3 signaling pathway and xenograft 
tumor growth in vivo. Compared with miR-216a treatment, 
anti-miR-216a treatment exhibited opposite effects throughout the 
entire experiment, confirming the inhibitory effect of miR-216a on 
pancreatic cancer by regulating the JAK2/STAT3 signaling pathway. 
The results provided evidence that miR-216a targeting JAK2 negatively 
regulated the development of pancreatic cancer cells and may be used to 
develop a miRNA-based therapeutic strategy against pancreatic cancer 
[127]. 
Similar to some other cancers, several TFs such as c-Myc and SIRT1 
were found as potential targets for miRNAs in PC. For example, up- 
regulation of miR-494 was shown to suppress pancreatic cancer cell 
proliferation through stimulation of apoptosis, G1-phase arrest, and 
senescence [128]. Furthermore, an OS-mediated miR-21 up-regulation 
was reported to increase cell migration in pancreatic cancer cells. It 
has been demonstrated that miR-21 promotes ROS generation through 
activating the mitogen-activated protein kinase (MAPK) pathway and 
inhibiting SOD2, SOD3 and sprouty homolog 2 (SPRY-2) expression 
[129]. 
9. Conclusion 
Since the discovery of miRNAs, it has been shown that these mole-
cules play a significant role in GI cancer pathology. On the other hand, 
numerous investigations have shown a critical function of oxidative 
stress in GI cancers. Indeed, it has been well-known that the develop-
ment and progression of GI cancers are mediated by both OS and miR-
NAs. In this view, several studies have also been performed to illuminate 
the cross-talking between the OS system and miRNAs and potential 
ROS/miRNA axis as molecular mechanisms underlying GI tumorigen-
esis. ROS transcriptionally or post-transcriptionally modulate the 
expression of miRNAs, and miRNAs target the key genes to regulate ROS 
in OS-derived tumors. Accumulating evidence indicated a reciprocal 
connection between OS signaling pathways and miRNA regulatory 
machines in GI cancer development and progression. In this review, we 
illustrated the function of miRNAs which target OS systems and 
described the biological cross-talk between OS systems and miRNAs in 
the GI system. Understanding the molecular mechanisms in which these 
systems reciprocally be regulated would improve our pathophysiolog-
ical insight into GI carcinogenesis, helping in future cancer therapeutics. 
Our results indicated that cross-talk between miRNAs and OS can affect 
GI carcinogenesis through modulating the genes involved in transcrip-
tional and post transcriptional regulation such as BCL2, KEAP1, NF-κB, 
SIRTs, Nrf2, PRXL2A, TLR4, hOGG1, FOXO4, Homeobox genes, ZEB1, 
p53 and KLF4. 
Recently, cancer therapy approaches focusing on miRNA and ROS 
have received special attention, so, the discovery of OS-responsive 
miRNAs may provide opportunities for developing novel anticancer 
strategies to overcome OS-mediated carcinogenesis. However, there are 
still a lot of therapeutic boundaries for OS-mediated cancers owing to 
the dual roles of ROS in tumorigenesis. 
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